Big Sky Resort Floorplan
Registered Attendees
Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:
- Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting
(You can edit your own abstract from My Account page as well)
NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.
- Full participant list, including joint meeting participants
- Printable Invoices and Invitation Letters
- Scholarship Information
- Lodging Information
Login to My Account page
This meeting took place in 2014
Here are the related meetings in 2021:
Harnessing the Microbiome for Disease Prevention and Therapy (EK12)
For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.
Exploiting and Understanding Chemical Biotransformations in the Human Microbiome (D1)
Organizer(s) Peter J. Turnbaugh, Curtis Huttenhower and Michael A. Fischbach
April 1—6, 2014
Big Sky Resort • Big Sky, MT USA
Discounted Abstract Deadline: Dec 5, 2013
Abstract Deadline: Jan 9, 2014
Scholarship Deadline: Dec 5, 2013
Discounted Registration Deadline: Feb 3, 2014
Supported by the Directors' Fund
Summary of Meeting:
The aggregate genomes of the trillions of microorganisms associated with the human body, the gut microbiome, extend our own human metabolism through transforming our diet and xenobiotic compounds, including host-targeted drugs and antibiotics. Furthermore, our microbial consortia encode a diverse array of biosynthetic machinery, making them an ideal source of novel natural products. This conference explores the major challenges that are emerging from this new area of study: 1) The biotransformation and resistance to therapeutics; 2) The discovery of natural products from microorganisms, in the context of the human microbiome and other systems; 3) Computational approaches to understanding microbial metabolism and biosynthesis; 4) The potential for synthetic biology to engineer microbiomes; 5) Therapeutic approaches to manipulate the microbiome; 6) Host-microbial signaling mechanisms; and 7) The consequences of microbial biotransformations and toxicity on host health and disease. This conference should foster long-lasting collaborative partnerships between individuals with wide-ranging expertise from both academia and industry. It incorporates the introduction of state-of-the-art techniques to existing areas of research, along with an attempt to identify general biological themes that influence multiple areas of research.
View Scholarships/Awards
The aggregate genomes of the trillions of microorganisms associated with the human body, the gut microbiome, extend our own human metabolism through transforming our diet and xenobiotic compounds, including host-targeted drugs and antibiotics. Furthermore, our microbial consortia encode a diverse array of biosynthetic machinery, making them an ideal source of novel natural products. This conference explores the major challenges that are emerging from this new area of study: 1) The biotransformation and resistance to therapeutics; 2) The discovery of natural products from microorganisms, in the context of the human microbiome and other systems; 3) Computational approaches to understanding microbial metabolism and biosynthesis; 4) The potential for synthetic biology to engineer microbiomes; 5) Therapeutic approaches to manipulate the microbiome; 6) Host-microbial signaling mechanisms; and 7) The consequences of microbial biotransformations and toxicity on host health and disease. This conference should foster long-lasting collaborative partnerships between individuals with wide-ranging expertise from both academia and industry. It incorporates the introduction of state-of-the-art techniques to existing areas of research, along with an attempt to identify general biological themes that influence multiple areas of research.
View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference
TUESDAY, APRIL 1
WEDNESDAY, APRIL 2
THURSDAY, APRIL 3
FRIDAY, APRIL 4
SATURDAY, APRIL 5
SUNDAY, APRIL 6
Conference Program Print | View meeting in 12 hr (am/pm) time
TUESDAY, APRIL 1
08:00—09:00
Keynote Address
*
Michael A. Fischbach,
Stanford University, USA
Elaine Holmes,
Imperial College London, UK
Trans-Omic Communication in Development and Control of Obesity
Trans-Omic Communication in Development and Control of Obesity
09:00—11:30
Microbial Interactions with Therapeutics
Gerry D. Wright,
McMaster University, Canada
Bacterial Inactivation of Anticancer Drugs
Bacterial Inactivation of Anticancer Drugs
Matthew R. Redinbo,
University of North Carolina at Chapel Hill, USA
Safely and Selectively Modulating the Mammalian Microbiome
Safely and Selectively Modulating the Mammalian Microbiome
Peter J. Turnbaugh,
University of California, San Francisco, USA
Contributions of the Human Gut Microbiome to Drug Metabolism
Contributions of the Human Gut Microbiome to Drug Metabolism
Arik Alper,
Yale University, USA
Short Talk: The Impact of Human Gut Microbial Community Variation on 5-ASA Metabolism
Short Talk: The Impact of Human Gut Microbial Community Variation on 5-ASA Metabolism
Libusha Kelly,
Albert Einstein College of Medicine, USA
Short Talk: Diverse and Mobile beta-Glucuronidases Populate Healthy Human Guts
Short Talk: Diverse and Mobile beta-Glucuronidases Populate Healthy Human Guts
11:30—12:45
NIH Resources and Funding Opportunities to Support Microbiome-Related Research
The goals of the session are (1) to provide an overview of NIH programs, resources, and funding opportunities to support research on understanding how the microbiome contributes to health and disease and (2) to provide a forum for participants to meet and interact with NIH program officials through discussion.
The workshop will include an introduction and brief presentations by NIH program staff on specific programs and funding opportunities, followed by discussions where participants can interact with NIH program staff in small groups.
The workshop will include an introduction and brief presentations by NIH program staff on specific programs and funding opportunities, followed by discussions where participants can interact with NIH program staff in small groups.
*
Padma Maruvada,
NIDDK, National Institutes of Health, USA
17:00—19:00
Biosynthesis of Small Molecules and Drug Discovery
*
Gerry D. Wright,
McMaster University, Canada
Emily P. Balskus,
Harvard University, USA
Discovery and Characterization of Disease-Associated Metabolic Pathways within the Human Gut Microbiota
Discovery and Characterization of Disease-Associated Metabolic Pathways within the Human Gut Microbiota
Michael A. Fischbach,
Stanford University, USA
Insights from a Global View of Secondary Metabolism: Small Molecules from the Human Microbiota
Insights from a Global View of Secondary Metabolism: Small Molecules from the Human Microbiota
Philip P. Strandwitz,
Northeastern University, USA
Short Talk: GABA Is a Growth Factor for Uncultured Bacteria from the Human Gut Microbiome
Short Talk: GABA Is a Growth Factor for Uncultured Bacteria from the Human Gut Microbiome
08:00—11:15
Computational Approaches to Understanding Microbial Metabolism and Biosynthesis
*
Aleksandar David Kostic,
Broad Institute, USA
Elhanan Borenstein,
University of Washington, USA
Metegenomic Systems Biology: Toward a Predictive Systems-Level Model of the Human Microbiome
Metegenomic Systems Biology: Toward a Predictive Systems-Level Model of the Human Microbiome
João B. Xavier,
Memorial Sloan-Kettering Cancer Center, USA
Modeling Intestinal Microbiota Dynamics during Antibiotic Treatment
Modeling Intestinal Microbiota Dynamics during Antibiotic Treatment
Curtis Huttenhower,
Harvard School of Public Health, USA
Multi'omic Characterization of the Gut Microbial Ecosystem for Diagnosis and Therapy in Inflammatory Disease
Multi'omic Characterization of the Gut Microbial Ecosystem for Diagnosis and Therapy in Inflammatory Disease
Rob Knight,
University of California, San Diego, USA
Microbial Communities Viewed Over Time and Space
Microbial Communities Viewed Over Time and Space
Patrick H. Bradley,
Gladstone Institutes, USA
Short Talk: Assessing the Stability of Protein Family Abundance in the Gut Microbiome
Short Talk: Assessing the Stability of Protein Family Abundance in the Gut Microbiome
Dan B. Knights,
University of Minnesota, USA
Short Talk: Linking Complex Host Genetics to Bacterial Dysbiosis in Inflammatory Bowel Disease
Short Talk: Linking Complex Host Genetics to Bacterial Dysbiosis in Inflammatory Bowel Disease
13:30—16:30
Workshop: Bioinformatics Tools (a Tutorial)
*
Curtis Huttenhower,
Harvard School of Public Health, USA
HUMAnN v2/ShortBRED
HUMAnN v2/ShortBRED
Morgan Langille,
Dalhousie University, Canada
PICRUSt/STAMP
PICRUSt/STAMP
Elhanan Borenstein,
University of Washington, USA
Metabolic Modeling
Metabolic Modeling
Rob Knight,
University of California, San Diego, USA
Evident/Qiita
Evident/Qiita
17:00—19:00
Impacts on Host Health and Disease
*
Heidi H. Kong,
National Institutes of Health, USA
Christian Jobin,
University of Florida, USA
Interaction between Genotoxic Bacteria and Host Environment Influences Colorectal Cancer Development
Interaction between Genotoxic Bacteria and Host Environment Influences Colorectal Cancer Development
Stanley L. Hazen,
Cleveland Clinical Foundation, USA
Links between Microbial Metabolism of Dietary Choline and Atherosclerosis
Links between Microbial Metabolism of Dietary Choline and Atherosclerosis
Eugene B. Chang,
University of Chicago, USA
Diet, Microbes and Genetics: The Perfect Storm to Inflammatory Bowel Diseases
Diet, Microbes and Genetics: The Perfect Storm to Inflammatory Bowel Diseases
Elaine Y. Hsiao,
University of California, Los Angeles, USA
Short Talk: A Commensal Bacterium of the Gut Microbiome Modulates Serum Metabolites and Ameliorates Behavioral Abnormalities in a Mouse Model of an Autism Risk Factor
Short Talk: A Commensal Bacterium of the Gut Microbiome Modulates Serum Metabolites and Ameliorates Behavioral Abnormalities in a Mouse Model of an Autism Risk Factor
08:00—11:00
Engineering Microbiomes
*
Curtis Huttenhower,
Harvard School of Public Health, USA
Sean Davies,
Vanderbilt University, USA
Genetically Engineered Therapeutic Bacteria
Genetically Engineered Therapeutic Bacteria
Christopher Voigt,
Massachusetts Institute of Technology, USA
Synthetic Metagenomics
Synthetic Metagenomics
Tom Van de Wiele,
Ghent University, Belgium
Simulating the Human Gut Microbiome
Simulating the Human Gut Microbiome
Liang Ma,
California Institute of Technology, USA
Short Talk: Using Microfluidics for Genetically Targeted Cultivation Validated by Isolation of a “Most Wanted” Microbe from the Human Gut
Short Talk: Using Microfluidics for Genetically Targeted Cultivation Validated by Isolation of a “Most Wanted” Microbe from the Human Gut
Yannan Zhao,
The Scripps Research Institute, USA
Short Talk: Self-Assembling Cyclic Peptides for Modulating the Gut Microbiome to Treat Atherosclerosis
Short Talk: Self-Assembling Cyclic Peptides for Modulating the Gut Microbiome to Treat Atherosclerosis
17:00—19:15
Therapeutics Approaches to Manipulating the Microbiome
*
Matthew R. Redinbo,
University of North Carolina at Chapel Hill, USA
Nathalie Delzenne,
Université Catholique de Louvain, Belgium
Prebiotic Approach: A Nutrition-Based Therapy to Tackle Metabolic Diseases Related to Malnutrition
Prebiotic Approach: A Nutrition-Based Therapy to Tackle Metabolic Diseases Related to Malnutrition
Alexander Khoruts,
University of Minnesota, USA
Human Fecal Microbiota Transplantation in Treatment of Clostridium difficile Infection: Metabolic Effects of Engraftment
Human Fecal Microbiota Transplantation in Treatment of Clostridium difficile Infection: Metabolic Effects of Engraftment
Liping Zhao,
Shanghai Jiao Tong University, China and Rutgers University, USA
Can We Follow Koch's Postulates for Hunting Down Human Obesity Bugs in Gut Microbiota?
Can We Follow Koch's Postulates for Hunting Down Human Obesity Bugs in Gut Microbiota?
08:00—11:15
Host-Microbial Interactions
*
Elaine Y. Hsiao,
University of California, Los Angeles, USA
Heidi H. Kong,
National Institutes of Health, USA
Host-Microbial Interactions in Healthy Skin and Dermatologic Disorders
Host-Microbial Interactions in Healthy Skin and Dermatologic Disorders
Margaret J. McFall-Ngai,
University of Hawai‘i at Mānoa, USA
Evolutionarily Conserved Signals of Host-Microbe Interaction: Lessons from the Squid-Vibrio Symbiosis
Evolutionarily Conserved Signals of Host-Microbe Interaction: Lessons from the Squid-Vibrio Symbiosis
Katherine P. Lemon,
Forsyth Institute, USA
Nose Picking for Progress: Mining Nasal Microbiota for New Insights into Pathobionts
Nose Picking for Progress: Mining Nasal Microbiota for New Insights into Pathobionts
Sven Pettersson,
Nanyang Technological University, Singapore
The Maternal Microbiome Influence Placenta Development and Function which can Influence Brain Function Later in Life
The Maternal Microbiome Influence Placenta Development and Function which can Influence Brain Function Later in Life
Charisse Petersen,
University of Utah, USA
Short Talk: Direct Detection of the Microbiota by T Cells Prevents Pathobiont Expansion to Maintain Homeostasis
Short Talk: Direct Detection of the Microbiota by T Cells Prevents Pathobiont Expansion to Maintain Homeostasis
Tim D. Spector,
King's College London, UK
Short Talk: Host Genetic Control of the Human Gut Microbiome: A Twin Study
Short Talk: Host Genetic Control of the Human Gut Microbiome: A Twin Study
17:00—18:15
Unintended Consequences of Antibiotic Use
*
Peter J. Turnbaugh,
University of California, San Francisco, USA
Tami Lieberman,
Massachusetts Institute of Technology, USA
Genomic Evolution and Diversification of a Pathogen within the Patient
Genomic Evolution and Diversification of a Pathogen within the Patient
Martin J. Blaser,
New York University School of Medicine, USA
Early Life Exposure to Antibiotics Changes Developmental Phenotypes
Early Life Exposure to Antibiotics Changes Developmental Phenotypes
18:15—19:15
Closing Keynote Address
*Session Chair †Invited, not yet responded.
We gratefully acknowledge support for this conference from:
We gratefully acknowledge the generous grant for this conference provided by:
We gratefully acknowledge additional support for this conference from:
|
|
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:
|
|
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:
Click here to view more of these organizations
|
If your organization is interested in joining these entities in support of Keystone
Symposia, please contact: Sarah Lavicka,
Director of Corporate Relations, Email: sarahl@keystonesymposia.org, Phone:+1 970-262-2690 Click here for more information on Industry Support and Recognition Opportunities. If you are interested in becoming an advertising/marketing in-kind partner, please contact: Nick Dua, Senior Director, Communications, Email: nickd@keystonesymposia.org, Phone:+1 970-262-1179 |
